Department of Health Research and Policy, Department of Medicine, Stanford University School of Medicine, Stanford, California; The Cardiovascular Research Center, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
The Cardiovascular Research Center, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; Division of Cardiology, Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark.
J Am Coll Cardiol. 2017 Apr 11;69(14):1761-1770. doi: 10.1016/j.jacc.2017.01.046.
The choice of either anatomical or functional noninvasive testing to evaluate suspected coronary artery disease might affect subsequent clinical management and outcomes.
This study analyzed the association of initial noninvasive cardiac testing in outpatients with stable symptoms, with subsequent use of medications, invasive procedures, and clinical outcomes.
We studied patients enrolled in a Danish nationwide register who underwent initial noninvasive cardiac testing with either coronary computed tomography angiography (CTA) or functional testing (exercise electrocardiography or nuclear stress testing) from 2009 to 2015. Further use of noninvasive testing, invasive procedures, medications, and medical costs within 120 days were evaluated. Risks of long-term mortality and myocardial infarction (MI) were analyzed using adjusted Cox proportional hazard models.
A total of 86,705 patients underwent either functional testing (n = 53,744, mean age 57.4 years, 49% males) or coronary CTA (n = 32,961, mean age 57.4 years, 45% males), and were followed for a median of 3.6 years. Compared with functional testing, there was significantly higher use of statins (15.9% vs. 9.1%), aspirin (12.7% vs. 8.5%), invasive coronary angiography (14.7% vs. 10.1%), and percutaneous coronary intervention (3.8% vs. 2.1%); all p < 0.001 after coronary CTA. The mean costs of subsequent testing, invasive procedures, and medications were higher after coronary CTA ($995 vs. $718; p < 0.001). Unadjusted rates of mortality (2.1% vs. 4.0%) and MI hospitalization (0.8% vs. 1.5%) were lower after coronary CTA than functional testing (both p < 0.001). After adjustment, coronary CTA was associated with a comparable all-cause mortality (hazard ratio: 0.96; 95% confidence interval: 0.88 to 1.05), and a lower risk of MI (hazard ratio: 0.71; 95% confidence interval: 0.61 to 0.82).
In stable patients undergoing initial evaluation for suspected coronary artery disease, coronary CTA was associated with greater use of statins, aspirin, and invasive procedures, and higher costs than functional testing. Coronary CTA was associated with a lower risk of MI, but a similar risk of all-cause mortality.
选择解剖学或功能性非侵入性检查来评估疑似冠状动脉疾病可能会影响后续的临床管理和结果。
本研究分析了门诊稳定症状患者初始非侵入性心脏检查与随后药物使用、介入程序和临床结果之间的关系。
我们研究了 2009 年至 2015 年间在丹麦全国登记处接受初始非侵入性心脏检查的患者,检查方法为冠状动脉计算机断层扫描血管造影(CTA)或功能检查(运动心电图或核应激试验)。在 120 天内进一步使用非侵入性检查、介入程序、药物和医疗费用进行评估。使用调整后的 Cox 比例风险模型分析长期死亡率和心肌梗死(MI)的风险。
共有 86705 名患者接受了功能检查(n=53744 名,平均年龄 57.4 岁,49%为男性)或冠状动脉 CTA(n=32961 名,平均年龄 57.4 岁,45%为男性),并进行了中位 3.6 年的随访。与功能检查相比,接受他汀类药物(15.9%比 9.1%)、阿司匹林(12.7%比 8.5%)、冠状动脉造影(14.7%比 10.1%)和经皮冠状动脉介入治疗(3.8%比 2.1%)的比例显著更高;所有 P 值均<0.001。接受冠状动脉 CTA 后,后续检查、介入程序和药物治疗的平均费用更高(995 美元比 718 美元;P<0.001)。未经调整的死亡率(2.1%比 4.0%)和 MI 住院率(0.8%比 1.5%)在冠状动脉 CTA 后均低于功能检查(均 P<0.001)。调整后,冠状动脉 CTA 与全因死亡率相当(风险比:0.96;95%置信区间:0.88 至 1.05),且 MI 风险降低(风险比:0.71;95%置信区间:0.61 至 0.82)。
在疑似冠状动脉疾病初始评估中接受初始检查的稳定患者中,与功能检查相比,冠状动脉 CTA 与他汀类药物、阿司匹林和介入程序的应用更广泛,且费用更高。冠状动脉 CTA 与 MI 风险降低相关,但全因死亡率风险相当。